Filter
829
Filtered Results: 829
Text search:
European
Monitoring
Centre
for
Drugs
and
Drug
Addiction
Featured
Recommendations
73
New Publications
163
Language
Document type
No document type
498
Studies & Reports
146
Guidelines
106
Manuals
39
Strategic & Response Plan
19
Fact sheets
8
Situation Updates
6
Training Material
4
Resource Platforms
3
Countries / Regions
Western and Central Europe
69
Eastern Europe
31
Global
28
Ukraine
24
India
23
Sierra Leone
15
Kenya
15
Africa
14
Nepal
12
Zambia
12
Ghana
11
Russia
11
Nigeria
10
Uganda
10
Eastern Europe and Central Asia
10
Ethiopia
8
Myanmar / Burma
8
Albania
8
Cambodia
7
South Africa
7
Tajikistan
7
Liberia
6
Tanzania
6
Namibia
6
Latin America and the Carribbean
6
Asia
6
Burkina Faso
5
Rwanda
5
Bangladesh
5
Malawi
5
West and Central Africa
5
South–East Asia Region
5
Georgia
5
Senegal
4
Philippines
4
Syria
4
Laos
4
Moldova
4
Congo, Democratic Republic of
3
Zimbabwe
3
Pakistan
3
Jordan
3
Germany
3
Thailand
3
North Macedonia
3
Lesotho
3
East and Southern Africa
3
Morocco
2
South Sudan
2
Lebanon
2
Indonesia
2
Mozambique
2
Eswatini/ Swaziland
2
Botswana
2
Sri Lanka
2
Middle East and North Africa
2
Estonia
2
Kyrgyzstan
2
Vietnam
2
Guinea
1
USA
1
Saudi Arabia
1
Cameroon
1
Iraq
1
Afghanistan
1
Turkey
1
Ireland
1
Sudan
1
Benin
1
Argentina
1
Brazil
1
Serbia
1
Hungary
1
Colombia
1
Greece
1
Mexico
1
Western Pacific Region
1
Fiji
1
Bhutan
1
Poland
1
Armenia
1
Qatar
1
Bulgaria
1
Lithuania
1
Iran
1
Uzbekistan
1
North America
1
Turkmenistan
1
Jamaica
1
Denmark
1
Tunisia
1
Norway
1
Portugal
1
Belarus
1
Authors & Publishers
Publication Years
Category
Countries
186
Clinical Guidelines
89
Public Health
46
Women & Child Health
24
Key Resources
15
Pharmacy & Technologies
15
Capacity Building
6
Toolboxes
HIV
153
Mental Health
120
TB
103
AMR
68
Pharmacy
38
COVID-19
23
Rapid Response
19
Refugee
15
NCDs
15
Global Health Education
13
Conflict
12
Ebola
10
NTDs
10
Planetary Health
9
Disability
7
Caregiver
6
Polio
4
Specific Hazards
3
Health Financing Toolbox
3
Natural Hazards
1
Zika
1
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
Getting to Zero
Sustainable Financing of National HIV Responses
People with mental disorders in low-income countries are at risk of being left behind during efforts to expand universal health coverage. Aim is to propose context-relevant strategies for moving towards universal health coverage ... people with mental disorders in Ethiopia.
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
Noncommunicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health ... development challenge in Turkey. This report provides evidence through three analyses that NCDs reduce economic output, and discusses potential options in response, outlining details of their relative returns on investment. An economic burden analysis shows that economic losses from NCDs are equivalent to 3.6% of gross domestic product. An intervention costing analysis provides an estimate of the funding required to implement a set of policy interventions for prevention and clinical interventions. A cost–benefit analysis compares these implementation costs with the estimated health gains and identifies which policy packages would give the greatest returns on investment.
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
The Road to Recovery. This synthesis report is based on three national studies on the evolution of the Ebola epidemic and its impact on Guinea, Liberia and Sierra Leone
Recently, a renewed interest in large-scale community health worker (CHW) programs has been seen globally. This renewal provides an opportune moment to take stock of issues and challenges such programs face ... what can be done to make them as effective as possible. With this in mind, this manual is intended to be used a practical guide for policymakers and program
managers wishing to develop or strengthen a CHW program, drawing lessons from other countries that have implemented CHW programs at-scale. Throughout, we discuss major policy and programmatic issues that decision-makers and planners need to consider when designing, implementing, scaling up or strengthening a national-level CHW program. We offer an overview
of specific challenges CHW programs face, country lessons, tools, and other resources that may be helpful, while incorporating relevant programmatic examples as much as possible.
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, ... the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, ... the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
В настоящей публикации представлен стратегический обзор ключевых сведений документа «Доклад о рынках наркотиков в ЕС 2016: глубокий анализ». В докладе собраны наши ...
